Partner in the Spotlight: Halio Dx
This month we feature our partners at HalioDx. HalioDx (https://www.haliodx.com/) is the pioneer of immuno-oncology diagnostic, a transforming approach of cancer care that benefits from novel and deep understanding of the tumour immune microenvironment. The company provides a unique and [...]
HalioDx Immunoscore® is independently reviewed in Molecular Diagnosis and Therapy
An independent review entitled “Immunoscore®: A Diagnostic Assay for Clinical Management of Colon Cancer” is published on March 30th, 2020 in Molecular Diagnosis and Therapy (Blair, H.A. Mol Diagn Ther (2020)[1] a specialized journal of Springer Nature group that provides researchers and [...]
COLOSSUS Partner in the Spotlight: Cancer Trials Ireland
Cancer Trials Ireland was established in 1996 under the name of Irish Cooperative Oncology Research Group (ICORG). A group of cancer consultants had the aim to create more opportunities for patients to access cutting edge treatments by putting a formal [...]
The COLOSSUS Spring 2020 newsletter is out!
Hear ye! Hear ye! The Spring 2020 COLOSSUS newsletter is out now! Read the latest update on the COLOSSUS translational study from partners at Cancer Trials Ireland, a spotlight feature on our partner HalioDx, the dissemination round-up and much more!
VHIO hosts interactive public meeting drawing together stakeholders in colorectal cancer treatment and care
Principal Investigators (PIs) involved in the COLOSSUS and MoTriColor projects hosted a packed public meeting for people with colorectal cancer, their carers, and relatives on February 27, 2020, at the Vall d´Hebron Institute of Oncology in Barcelona. Berta Colldeforns Riera [...]
VIB hosts Tumor Heterogeneity, Plasticity and Therapy meeting, 14-15 May 2020- travel grants are available
Our partners VIB, a non-profit life sciences research institute in Belgium, is pleased to announce the first Tumor Heterogeneity, Plasticity and Therapy meeting which will be held on May 14-15, 2020 in the historical city of Leuven, Belgium. The upcoming deadlines [...]